Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | ITGB2 | P05107 | 13/20 | 0.45 |
| ▸ | ICAM1 | P05362 | 13/20 | 0.45 |
| ▸ | ITGAL | P20701 | 13/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15498050 | 0.88 | HDAC6 (0.52) | HDAC6ITGB2ICAM1ITGALPIK3CA | |
| SCHEMBL13167800 | 0.87 | PIK3CA (0.47) | HDAC6ITGB2ICAM1ITGALPIK3CA | |
| SCHEMBL13666028 | 0.85 | MAPK14 (0.53) | HDAC6ITGB2ICAM1ITGALMAPK14 | |
| SCHEMBL13821871 | 0.85 | ITGB2 (0.50) | HDAC6ITGB2ICAM1ITGAL | |
| SCHEMBL12651397 | 0.85 | PIK3CA (0.43) | HDAC6ITGB2ICAM1ITGALPIK3CA | |
| SCHEMBL10156372 | 0.83 | PIK3CA (0.47) | HDAC6ITGB2ICAM1ITGALPIK3CA | |
| SCHEMBL879401 | 0.83 | ITGB2 (0.63) | ITGB2ICAM1ITGAL | |
| SCHEMBL10157546 | 0.82 | ITGB2 (0.49) | ITGB2ICAM1ITGAL | |
| SCHEMBL21004187 | 0.81 | ITGB2 (0.56) | ITGB2ICAM1ITGAL | |
| SCHEMBL10130071 | 0.81 | ITGB2 (0.55) | ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170143693-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | SARCODE BIOSCIENCE INC. (US) | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170143693-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | ICAM1, VCAM1, ITGAL | HDAC6 1250/4885ITGB2 8/4885ICAM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.